Business Description
Bioventix PLC
ISIN : GB00B4QVDF07
Description
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.87 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 116.76 | |||||
| Beneish M-Score | -2.17 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.1 | |||||
| 3-Year EBITDA Growth Rate | 7.7 | |||||
| 3-Year EPS without NRI Growth Rate | 4.7 | |||||
| 3-Year FCF Growth Rate | 1.6 | |||||
| 3-Year Book Growth Rate | -1.3 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 28.41 | |||||
| 9-Day RSI | 32.08 | |||||
| 14-Day RSI | 35.41 | |||||
| 6-1 Month Momentum % | 23.81 | |||||
| 12-1 Month Momentum % | 18.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.04 | |||||
| Quick Ratio | 6.7 | |||||
| Cash Ratio | 3.22 | |||||
| Days Inventory | 240.04 | |||||
| Days Sales Outstanding | 106.33 | |||||
| Days Payable | 430.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.65 | |||||
| Dividend Payout Ratio | 0.93 | |||||
| 3-Year Dividend Growth Rate | 19.8 | |||||
| Forward Dividend Yield % | 3.65 | |||||
| 5-Year Yield-on-Cost % | 8.93 | |||||
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | 3.65 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 93.75 | |||||
| Operating Margin % | 79.09 | |||||
| Net Margin % | 63.74 | |||||
| FCF Margin % | 58.77 | |||||
| ROE % | 76.55 | |||||
| ROA % | 68.16 | |||||
| ROIC % | 143.19 | |||||
| ROC (Joel Greenblatt) % | 290.57 | |||||
| ROCE % | 95.42 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 26.47 | |||||
| Forward PE Ratio | 24.1 | |||||
| PE Ratio without NRI | 26.47 | |||||
| Shiller PE Ratio | 35.74 | |||||
| Price-to-Owner-Earnings | 24.42 | |||||
| PEG Ratio | 3.23 | |||||
| PS Ratio | 16.89 | |||||
| PB Ratio | 20.03 | |||||
| Price-to-Tangible-Book | 20.02 | |||||
| Price-to-Free-Cash-Flow | 28.72 | |||||
| Price-to-Operating-Cash-Flow | 28.7 | |||||
| EV-to-EBIT | 20.36 | |||||
| EV-to-Forward-EBIT | 18.2 | |||||
| EV-to-EBITDA | 20.13 | |||||
| EV-to-Forward-EBITDA | 18.05 | |||||
| EV-to-Revenue | 16.2 | |||||
| EV-to-Forward-Revenue | 14.59 | |||||
| EV-to-FCF | 27.56 | |||||
| Price-to-Projected-FCF | 2.54 | |||||
| Price-to-DCF (Earnings Based) | 0.96 | |||||
| Price-to-DCF (FCF Based) | 0.95 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.34 | |||||
| Price-to-Graham-Number | 4.85 | |||||
| Price-to-Net-Current-Asset-Value | 22.29 | |||||
| Price-to-Net-Cash | 60.07 | |||||
| Earnings Yield (Greenblatt) % | 4.91 | |||||
| FCF Yield % | 3.54 | |||||
| Forward Rate of Return (Yacktman) % | 11.13 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bioventix PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | 13.596 | ||
| EPS (TTM) (£) | 1.634 | ||
| Beta | 0.68 | ||
| Volatility % | 18.15 | ||
| 14-Day RSI | 35.41 | ||
| 14-Day ATR (£) | 1.328094 | ||
| 20-Day SMA (£) | 45.06 | ||
| 12-1 Month Momentum % | 18.18 | ||
| 52-Week Range (£) | 34.4 - 51 | ||
| Shares Outstanding (Mil) | 5.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bioventix PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bioventix PLC Stock Events
| Event | Date | Price(£) | ||
|---|---|---|---|---|
| No Event Data | ||||
Bioventix PLC Frequently Asked Questions
What is Bioventix PLC(LSE:BVXP)'s stock price today?
The current price of LSE:BVXP is £43.25. The 52 week high of LSE:BVXP is £51.00 and 52 week low is £34.40.
When is next earnings date of Bioventix PLC(LSE:BVXP)?
The next earnings date of Bioventix PLC(LSE:BVXP) is 2024-10-30 Est..
Does Bioventix PLC(LSE:BVXP) pay dividends? If so, how much?
The Dividend Yield %  of Bioventix PLC(LSE:BVXP) is 3.65% (As of Today), Highest Dividend Payout Ratio of Bioventix PLC(LSE:BVXP) was 0.93. The lowest was 0.49. And the median was 0.57. The  Forward Dividend Yield % of Bioventix PLC(LSE:BVXP) is 3.65%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers